#USA #Boston #Drug Development #GBI Biomanufacturing #SmartScale™

GBI Biomanufacturing's Innovative Leap: The Launch of SmartScale™

In an exciting development for the biopharmaceutical industry, GBI Biomanufacturing, based in Florida, is set to launch its groundbreaking SmartScale™ GMP Solutions platform at the upcoming BioProcess International (BPI) East 2026 event in Boston. This innovative solution aims to create a streamlined, efficient path for early-stage biologics developers, facilitating quicker transitions from laboratory research to human clinical trials.

A Game-Changer for Drug Developers

During the BPI East conference, Dr. Jesse McCool, the CEO of GBI Biomanufacturing, plans to showcase this cutting-edge platform and share insights on its potential impact on drug development. The SmartScale™ platform is designed to enhance the production of good manufacturing practice (GMP) materials crucial for first-in-human studies, thus significantly accelerating the process for therapeutics developers.

Dr. McCool comments, "When developing life-saving therapies, speed and simplicity can make a significant difference. Many early-stage drug developers need a more efficient path to obtain the GMP material required to reach the clinic. SmartScale™ was designed to help close that gap by providing a right-sized manufacturing approach that accelerates the journey to first-in-human studies."

This platform represents a collaborative achievement involving key industry players—ATUM and Thomson Instrument Company—who have contributed expertise and technology to streamline various processes critical to drug development.

Accelerated Pathway to Clinical Trials

Bringing a biologic therapy from initial development to manufacturing and ultimately to human trials is no small feat; it often requires investments of $5 million or more. With the introduction of SmartScale™, GBI Biomanufacturing aims to lower the financial barrier associated with early clinical evaluations, thereby reducing development risks whilst simultaneously shortening timelines.

Dr. McCool emphasizes the platform’s efficiency: “SmartScale™ is a stable pool-based manufacturing platform that can deliver GMP material for first-in-human studies in as little as eight months. Our goal is to help customers reach the crucial milestone of generating human clinical data that supports future regulatory and commercial decisions.”

The SmartScale™ platform is particularly aligned with the FDA's Operation TrialBlazer initiative. This initiative aims to accelerate the development of innovative therapies and revamp drug development pathways to be more responsive and adaptive to new challenges in the healthcare landscape.

The Technology Behind SmartScale™

At the heart of SmartScale™ lies a series of sophisticated technologies that enhance manufacturing processes without compromising on quality. By leveraging stable pool technology and optimizing bioprocessing workflows, GBI Biomanufacturing seeks to support the goal of generating clinical material more effectively while facilitating the collection of critical data during early stages of development.

To achieve this, GBI has integrated ATUM's Leap-In Transposase® cell lines into the SmartScale™ program. This collaboration promises to maximize drug substance yield, enabling developers to harness the full potential of their biologics even at small scales.

Sam Ellis, CEO of Thomson Instrument Company, also lauded this initiative, saying, "The Optimum Growth® Flask was designed to simplify scale-up while maintaining high-performance cell culture conditions. As part of the SmartScale™ platform, our technology helps streamline the transition from research and development into GMP manufacturing."

Responding to Global Biopharmaceutical Competition

As competition in the biopharmaceutical arena intensifies globally, the partnership between GBI Biomanufacturing, ATUM, and Thomson Instrument Company emerges as a crucial response. The combined expertise aims to create an integrated solution tailored specifically for first-in-human development programs.

This initiative reflects a commitment to enabling drug developers to reduce timelines, achieve greater operational efficiency, and hasten the path toward bringing innovative therapies to the market.

The successful launch of SmartScale™ signifies both an exciting milestone for GBI Biomanufacturing and a pivotal moment for innovations in drug development methodologies. As regulators and industry leaders continue to push for quicker routes to clinical evaluation, solutions like SmartScale™ represent a necessary evolution in the drive for effective, life-saving medicinal therapies.

Media Contact: Mike Smith, PR Counsel for GBI Biomanufacturing, [email protected], 703-623-3834